Overall Scientific Theme and Programme
Internationally, Health Technology Assessment (HTA) is considered the leading approach to govern health systems, manage innovation and inform disinvestment decisions in public and private settings. An effective system requires an integrated environment where interactions can occur at all levels—international, national, regional and local. Each level holds different responsibilities and is characterized by a variety of stakeholders involved both in the provision and use of HTAs for decision-making. International collaborations, national and regional HTA bodies and hospital-based HTA units or functions all contribute to a sustainable healthcare network that requires coordination to improve clinical and organisational processes and patient outcomes.
HTA, however, is now evolving towards an integrated network or “ecosystem” where local needs can be addressed, thanks to both local and global evidence used to support effective and sustainable decisions. This new scenario implies adaptation and changes in methodologies and tools, professional competencies and technical solutions with computational capability for big data analysis.
Our new ecosystem is shaped by new and old forms of cooperation with examples of integration now emerging or evolving in different areas of the world, moving beyond the historic global collaboration proposed by the International Network of Agencies for Health Technology Assessment (INAHTA) in 1993. For example, the European Network of Health Technology Assessment (EUnetHTA) currently leads HTA collaboration among member states by creating a structured environment in which cooperation in HTA is flourishing. By the end of Joint Action 3 in 2019, it is expected to sustain its own HTA system that is fully integrated within the European regulatory framework for both drugs and medical devices. In the Americas, Health Technology Assessment Network of the Americas (RedETSA) is proposing a new model for collaboration and, similarly, Asian countries have started a new experience through HTAsiaLink. Many other examples are reported worldwide.
The 2017 HTAi Annual Meeting in Rome, Italy aims to collect experiences to promote a deeper understanding of the opportunities and challenges of different approaches and to foster collaboration in HTA and integration between HTA and regulatory systems. We will host enriching discussions around what we can achieve beyond borders and how we may impact healthcare decision-making through HTA at the global level.
The plenary themes are:
The Annual Meeting in Rome will provide an opportunity to consider:
1. Methods in HTA
a. Research on methods
b. Literature retrieval
c. Evidence transferability and generalisability
d. Clinical effectiveness
f. Costs and economic evaluation
g. Ethical, social and legal aspects
h. Big data analysis and use of Real World Data for HTA
i. Precision medicine
2. Policy issues in HTA
a. Integrating regulation and HTA
b. Value-based health policy
c. Capacity building in HTA
d. Country-specific HTA
e. Regional HTA Networks and comparative HTA systems
3. Hospital-based HTA
4. HTA and Clinical Practice Guidelines
5. Stakeholder involvement in HTA
a. Patient involvement
b. Public involvement
c. Engagement of Health care professionals
6. Other topics
Applicants are asked to select from the above list of topics to identify the best fitting theme for their submitted abstract. Accordingly, reviewers are asked to select from the same list of topics to disclose their area of expertise and to match applications with the most knowledgeable reviewer.
HTAi will also look to ensure strong representation of methods, students and presenters from low and middle-income countries.
Panel and Workshop Submissions
Poster & Oral Submissions
1) Submission deadlines are different based on submission type. Please note below important dates regarding abstract submissions.
2) Submission details
3) Review, Acceptance and Notification
All abstracts will be peer reviewed by experts who are assembled and managed by the HTAi International Scientific Programme Committee (ISPC). Panel and workshop submissions will be reviewed directly by the ISPC. Oral and poster submissions will be reviewed by a broad group of reviewers, coordinated by the ISPC Secretariat, which will include ISPC members and selected group of experts in the HTA field.
Final decisions about inclusion and organization of the programme will be made by the ISPC, led by the ISPC Co-Chairs. Receipt of abstract submission will be acknowledged via e-mail prior to submission close for each category.
Confirmation of attendance and registration for the Annual Meeting must be submitted by Friday, March 31, 2017, to ensure inclusion in the Annual Meeting Programme. Corresponding authors will receive notification of acceptance or rejection of their abstracts before this date. Please check important dates for the conference.
Submission of abstracts constitutes the authors’ consent to have their abstracts published on the HTAi 2017 Website, Mobile App, within the Programme and an Abstract Book.
Accepted abstracts of oral and poster presentations will be published in a Supplementary Issue of the International Journal of Technology Assessment in Health Care. Once abstracts have been accepted for the HTAi meeting there will be an editing process and if any major changes are recommended these will be communicated to the first author. Prior to acceptance in the journal, a Copyright Assignment Form (please find the form here) must be completed and authors will be notified of the deadline for this. The Supplementary Issue will be published ahead of the meeting.
Additional Qualitative Criteria
1) Appropriateness to HTAi
The concept of the abstract should be appropriate to HTAi, and in alignment with the main themes of the Annual Meeting. Panels and workshops should have high quality speakers from different perspectives.
2) Original and Innovative Contribution
Abstracts with original and innovative ideas will receive a higher score. In particular:
Moreover, in the scoring systems gender balance, student’s, LOC, HTAi Interest Groups and LMIC contribution will be taken into consideration. LOC, HTAi partners and interest group chairs need to contact ISPC Co-Chairs with their relevant abstract submission numbers to inform about their official submissions.
3) Abstract Structure & Quality
a) Workshops and panel abstracts must have the following structure:
Title: must not exceed 100 characters
Introduction: Including scientific background and explanation of rationale, and a clear statement of the problem. Must be clearly stated to achieve the highest score.
Structure of the session: Please explain the structure of your workshop/panel (e.g. participants, timing, format of interaction, etc.) and your plans to generate a vibrant discussion or working environment.
Panel/Workshop outcome and objectives: Please explain what you would like to accomplish during your workshop/panel session and what are the benefits and takeaways for the audience/participants.
References: Authors might include up to three references
b) Oral and poster presentation abstracts must have the following structure:
Title: must not exceed 70 characters
Introduction: Including scientific background and explanation of rationale, and a clear statement of the problem, issue, study goal, objectives, and/or research hypothesis. Must be clearly stated to achieve the highest score.
Methods: For quantitative and related studies, a clear statement of perspective, data collected, sources of data, analyses done including statistical testing, policy analysis of alternatives, issues examined, and the like. Clear description required of populations studied, method to accrue populations, and sample frame and analytic techniques. For conceptual, institutional, organizational, or policy papers, authors of abstracts should provide a concise description of the content of the paper or report that would be presented.
Results: Present most important study findings, including (if relevant) generalisability to other populations, health systems or countries.
Conclusions: Should address the question, “What do these results mean for population health, resource allocation/cost, and/or health and medical care policy?” Provide a concise statement on most important findings or policy implications. Should address next steps and/or best course of action, and study limitations.
References: Authors might include up to three references.